Non-viral Therapies Opportunity to engage with Anjarium’s focus on non-viral gene therapies and DNA construct platforms to explore collaborations, licensing, or pilot programs that leverage their synthetic DNA constructs across AAV, mRNA, and Lentivirus applications.

Executive Team Growth With recent key executive hires (CTO, CEO, CBO, COO) and an expanding board, there is a potential to offer strategic partnerships, advisory roles, or early access programs aligned with their roadmap for scalable gene therapy tools.

Strategic Funding Having secured significant funding and notable investors, there is an opening to propose co-development financing, additional grant-ready collaborations, or joint ventures that accelerate productization of their customizable DNA constructs.

Boutique Scale Small team size (2–10 employees) suggests a high value on scalable external partnerships and service-oriented collaborations; position as a lean, flexible supplier for research-grade and development-stage DNA constructs and related tooling.

Swiss Biotech Access Headquartered in Switzerland and serving global partners, present value propositions around near-term clinical and research collaborations, regulatory-ready workflows, and supply chain reliability to global biopharma and academic customers seeking non-viral gene therapy solutions.